Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Determining exposure underreporting in pharmacoepidemiologic case-control studies: methods and example.

D A Lane1, M S Kramer

  • 1Dipartimento di Economia Politica, Università degli Studi di Modena, Italy.

Journal of Clinical Epidemiology
|December 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stop and Go: Barriers and Facilitators to Care Home Research.

The Journal of frailty & aging·2023
Same author

Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.

Journal of thrombosis and haemostasis : JTH·2018
Same author

ADAMTS-13 and von Willebrand factor: a dynamic duo.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.

Journal of internal medicine·2017
Same author

Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity: reply.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Conformational quiescence of ADAMTS-13 prevents proteolytic promiscuity.

Journal of thrombosis and haemostasis : JTH·2016
Same journal

Using an Open Science Checklist in Grant Proposal Reviews to Predict Reproducibility of Funded Publications.

Journal of clinical epidemiology·2026
Same journal

A comparison of five statistical methods used to analyse longitudinal EORTC QLQ-C30 quality of life scores in randomised controlled trials: a simulation study.

Journal of clinical epidemiology·2026
Same journal

Sample Size Determination for Decision-centered Pragmatic Trials.

Journal of clinical epidemiology·2026
Same journal

Many multicenter randomized controlled trials do not account for center effect: a methodological review.

Journal of clinical epidemiology·2026
Same journal

Patient Acceptability of the Modified Zelen Approach to Randomized Trials - A Survey of the CAPS THA Cohort.

Journal of clinical epidemiology·2026
Same journal

Corrigendum to SPICE-GRADE: simultaneous processing of indirect causal evidence in complex pathways using GRADE - an exploratory case study. [Journal of Clinical Epidemiology, 194C (2026) 112219].

Journal of clinical epidemiology·2026
See all related articles

Pharmacoepidemiologic studies may suffer from underreported drug exposures. New methods using study data and external information can quantify this underreporting, crucial for assessing recall bias in case-control studies.

Area of Science:

  • Pharmacoepidemiology
  • Biostatistics
  • Drug Safety

Background:

  • Case-control studies often rely on self-reported drug exposure data.
  • Underreporting of exposures and differential reporting between cases and controls can bias study results.
  • Recall bias is a significant concern in pharmacoepidemiologic research.

Purpose of the Study:

  • To introduce and validate novel procedures for quantifying underreporting of drug exposures in case-control studies.
  • To assess the impact of underreporting on the International Primary Pulmonary Hypertension Study (IPPHS) data.
  • To determine if study findings may be influenced by recall bias.

Main Methods:

  • Developed two procedures utilizing case-control study data combined with external sales, demographic, and market research data.

Related Experiment Videos

  • Applied these procedures to data from the IPPHS, investigating the link between anorexigens and pulmonary hypertension.
  • Analyzed exposure reporting patterns for dexfenfluramine in relation to study year.

    • Main Results:

    • Significant underrepresentation of dexfenfluramine exposures starting before 1989 was found in IPPHS controls compared to later exposures (P<0.01).
    • No similar underrepresentation of early exposures was observed for IPPHS cases.
    • Exposure data for controls from 1990-1992 were consistent with the absence of underreporting.

    Conclusions:

    • The developed procedures can effectively investigate the extent of exposure underreporting in pharmacoepidemiologic case-control studies.
    • Underreporting of early dexfenfluramine exposure in controls may have impacted previous IPPHS findings.
    • These methods, with appropriate assumptions and data, can help mitigate the effects of recall bias.